SCHEMBL3776229

SCHEMBL3776229

COc1ccc(C)cc1-c1ccc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)nn1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.46
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TP53 P04637 2/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
AURKA O14965 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762981 0.92 RAB9A (0.47) HRH3RAB9ANPC1MEN1KMT2A
SCHEMBL3773905 0.91 HRH3 (0.45) HRH3RAB9AMEN1KMT2ATP53
SCHEMBL3773851 0.91 HRH3 (0.47) HRH3ALDH1A1KDM4ETDP1
SCHEMBL3773698 0.89 HRH3 (0.44) HRH3RAB9AMEN1KMT2AALDH1A1
SCHEMBL3774737 0.89 HRH3 (0.50) HRH3RAB9ANPC1MEN1KMT2A
SCHEMBL3772011 0.88 MAPT (0.44) HRH3ALDH1A1MAPT
SCHEMBL3769122 0.87 RAB9A (0.44) HRH3RAB9ANPC1MEN1KMT2A
SCHEMBL3779373 0.87 RAB9A (0.48) HRH3RAB9AMEN1KMT2AALDH1A1
SCHEMBL3779376 0.86 HRH3 (0.46) HRH3RAB9ANPC1TP53ALDH1A1
SCHEMBL3767484 0.86 MAPK1 (0.49) HRH3RAB9ANPC1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885RAB9A 3824/4885NPC1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.